Valentin Piech
Venture Partner @ BioMedPartners
Basel, Switzerland
Valentin Piech is a seed investor at BioMedPartners in Basel focused on Health Care and Life Science. Valentin Piëch is the Founder of VP Venture Partners.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Valentin Piech invests in
Stages Valentin Piech invests in
Countries Valentin Piech invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (100%)
- Life Science 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Seed 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CollimateHealth is creating a clinically scalable microbeam radiation technology that will revolutionize the treatment of cancer. | $6.9M / Seed / Jun 12, 2026 | ||
| Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $63.2M / Series B / May 03, 2022 |
Co-Investors
About BioMedPartners
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
BioMedPartners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fiona Lauscher
Office Manager
|
|||
Karl Deres
Venture Partner
|
|||
Markus Hosang
General Partner
|
|||
Patrick Burgermeister
Partner
|
|||
Stefan Fäs
Chief Financial Officer & Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Valentin Piech invest in?
Valentin Piech invests primarily in Health Care, Life Science and Therapeutics startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Valentin Piech?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Valentin Piech last invest?
The most recent investment recorded for Valentin Piech closed in Jun 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
